



## Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference

February 8, 2022

CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will present at the SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022.

Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, will provide an overview of the company at 3:40PM EDT on February 16. A link to the webcast will be available at <https://investors.werewolf.com/news-and-events/events>. An archived replay will be available for approximately 30 days following the presentation.

### About Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit [www.werewolf.com](http://www.werewolf.com).

### Investor Contact:

Jonathan M. Nugent  
Stern IR  
212.698.8698  
[jonathan.nugent@sternir.com](mailto:jonathan.nugent@sternir.com)

### Media Contact:

Amanda Sellers  
VERGE Scientific Communications  
301.332.5574  
[asellers@vergescientific.com](mailto:asellers@vergescientific.com)

### Company Contact:

Ellen Lubman  
Chief Business Officer  
Werewolf Therapeutics  
[elubman@werewolf.com](mailto:elubman@werewolf.com)